Illimis Therapeutics
Latest round
- Series B
Last raised
- Jul 2025
Total raised
- $59M
Investors
- 25
About Illimis Therapeutics
Founded in 2021 in Seoul, South Korea, Illimis Therapeutics specializes in treatments for central nervous system disorders.Illimis Therapeutics specializes in the development of innovative treatments for central nervous system (CNS) disorders, particularly focusing on Alzheimer's disease through its flagship product, GAIA-Aß. This approach aims to enhance the safety profile of existing Alzheimer's treatments and improve patient outcomes. Utilizing TAM receptors instead of Fc receptors, Illimis aims to reduce neuroinflammation and foster a healthier immune environment in the brain. The GAIA platform is currently in the preclinical stages and targets both Alzheimer's patients and their families seeking better quality of life.In 2023, Illimis Therapeutics reported no revenue. The company aims to expand its market reach, with specific targets for international markets that have high unmet needs in CNS treatment, with further details on the regions targeted to be outlined as the product progresses. As Illimis continues to develop its pipeline, they will also focus on establishing a B2B model that directly connects with healthcare providers and institutions, facilitating broader access to its innovative therapies.
Who invested in Illimis Therapeutics
25 investors across 3 rounds
See all investors in Illimis Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Illimis Therapeutics
Who invested in Illimis Therapeutics?
Illimis Therapeutics has 25 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Illimis Therapeutics raised?
Illimis Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Illimis Therapeutics last raise money?
Illimis Therapeutics's most recent round on record is a Series B, in Jul 2025.
What does Illimis Therapeutics do?
Founded in 2021 in Seoul, South Korea, Illimis Therapeutics specializes in treatments for central nervous system disorders.
Where is Illimis Therapeutics headquartered?
Illimis Therapeutics is headquartered in Seoul, South Korea.
Which VCs invest in companies like Illimis Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Illimis Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Illimis Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.